Jiangsu Aidea Pharmaceutical Co (SHSE:688488) Short-Term Debt & Capital Lease Obligation : ¥394.8 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Jiangsu Aidea Pharmaceutical Co Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Jiangsu Aidea Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥394.8 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Jiangsu Aidea Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥87.1 Mil.

Jiangsu Aidea Pharmaceutical Co Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Jiangsu Aidea Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Aidea Pharmaceutical Co Short-Term Debt & Capital Lease Obligation Chart

Jiangsu Aidea Pharmaceutical Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.02

4.23

147.27

339.41

393.77

Jiangsu Aidea Pharmaceutical Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															439.06	388.44	386.55	393.77	394.77

Jiangsu Aidea Pharmaceutical Co Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Jiangsu Aidea Pharmaceutical Co Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Jiangsu Aidea Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Jiangsu Aidea Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Aidea Pharmaceutical Co Ltd (SHSE:688488) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 2 Liuzhuang Road, Hanjiang District, Jiangsu Province, Yangzhou, CHN, 225008

Website

http://www.aidea.com.cn

Jiangsu Aidea Pharmaceutical Co Ltd produces and sells human-derived protein products, and also develops some generic drug businesses and distributes Abbott's HIV diagnostic equipment and reagents. The company focuses on development of new chemical entities of anti-tumor, anti-virus and cardiovascular areas, among which two NCE drugs for the treatment of Cancer and AIDS have been approved.

Executives

Wang Jun	Directors, senior managers
Fu He Liang	Director, core technical staff
Zhang Jie	Directors, senior managers
Yuan Yu	Core technical personnel
Su Gu Fang	Core technical personnel
Zhang Ji Bing	Core technical personnel
Wang Guang Rong	Directors, senior managers
Yu Ke	Directors, senior managers

Jiangsu Aidea Pharmaceutical Co Headlines

No Headlines